Applicants: Gregory B. Wilson et al.

Serial No.: 09/776,010 Filed: February 2, 2001

Page 2

## Listing of Claims

- 1-31. (Canceled)
- 32. (Currently Amended) A cell free fluid consisting essentially of a mammary gland secretion colostrum of a human herpesvirus-6A-immunized lactating bovid, wherein the colostrum has removed from it cells, casein and fat.
- 33. (Currently Amended) A cell-free fluid consisting essentially of a mammary gland secretion colostrum of a human herpesvirus-6B-immunized lactating bovid, wherein the colostrum has removed from it cells, casein and fat.
- 34. (Canceled)
- 35. (Canceled)
- 36. (Currently Amended) <u>A lyophilate of the The cell free</u> fluid of claim 32 <del>in the form of a lyophilized product</del>.
- 37. (Currently Amended) A lyophilate of the The cell-free fluid of claim 33 in the form of a lyophilized product.
- 38. (Currently Amended) A pharmaceutical composition comprising an effective amount of the cell free fluid of claim 32 and a pharmaceutically acceptable carrier.
- 39. (Currently Amended) A pharmaceutical composition comprising an effective amount of the cell free fluid of claim 33 and a pharmaceutically acceptable carrier.
- 40. (Currently Amended) A method of treating chronic fatigue syndrome in a human which comprises orally administering to the human (i) an amount of a cell free fluid consisting essentially of a mammary gland secretion colostrum of a

Applicants: Gregory B. Wilson et al.

Serial No.: 09/776,010 Filed: February 2, 2001

Page 3

human herpesvirus-6A immunized lactating mammal bovid, wherein the colostrum has removed from it cells, casein and fat and (ii) an amount of a cell free fluid consisting essentially of a mammary gland secretion colostrum of a human herpesvirus-6B immunized lactating mammal bovid wherein the colostrum has removed from it cells, casein and fat, which fluids are administered in amounts effective to treat chronic fatigue syndrome in the human.

- 41. (Canceled)
- 42. (Previously Presented) A method of treating chronic fatigue syndrome in a human which comprises orally administering to the human the pharmaceutical composition of claim 38, so as to thereby treat chronic fatigue syndrome in the human.
- 43. (Previously Presented) A method of treating chronic fatigue syndrome in a human which comprises orally administering to the human the pharmaceutical composition of claim 39, so as to thereby treat chronic fatigue syndrome in the human.
- 44. (Canceled)
- 45. (Canceled)
- (Currently Amended) A pharmaceutical composition comprising an amount of (i) a cell-free fluid consisting essentially of a mammary gland secretion colostrum of a human herpesvirus-6A immunized lactating mammal bovid, wherein the colostrum has removed from it cells, casein and fat, and (ii) an amount of a cell-free fluid consisting essentially of a mammary gland secretion colostrum of a human herpesvirus-6B immunized lactating mammal bovid, wherein the colostrum has removed from it

Applicants: Gregory B. Wilson et al.

Serial No.: 09/776,010 Filed: February 2, 2001

Page 4

cells, casein and fat, and (iii) a pharmaceutically acceptable carrier, wherein the fluids are present in amounts effective to treat chronic fatigue syndrome in a human subject and a pharmaceutically acceptable carrier.

47. (Previously Presented) A method of treating chronic fatigue syndrome in a human which comprises orally administering to the human the pharmaceutical composition of claim 46, so as to thereby treat chronic fatigue syndrome in the human.